home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Targeting Leukemia

  January, 17 2006 10:05
your information resource in human molecular genetics
A new inhibitor of Bcr-abl kinase, a key therapeutic target for treating chronic myelogenous leukemia (CML), is reported in the February 2006 issue of Nature Chemical Biology. CML is a common form of leukemia that is typically characterized by two genes, BCR and ABL1, connecting together when they should be separate. The resulting fusion protein causes cellular signaling pathways to be on when they should be off and contributes to the development of CML. CML patients are developing resistance to the current clinical inhibitor of these signaling pathways, so there is a strong need to find therapeutics with alternative mechanisms of action.

Nathanael Gray and colleagues screened for new Bcr-abl inhibitors by looking for small molecules that were toxic to Bcr-abl-expressing cells but not normal cells. A compound identified in the screen was shown to selectively inhibit leukemic cell lines and use a different mechanism to bind to the protein from the current inhibitor. The highly selective Bcr-abl inhibition and distinct mode of action suggest that this inhibitor is a valuable lead for developing new CML treatments.

Author contact:

Nathanael Gray (Genomics Institute of the Novartis Foundation, San Diego, CA, USA)
E-mail: ngray@gnf.org

Abstract available online.

(C) Nature Chemical Biology press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.